期刊文献+

2021—2023年某三甲医院替加环素临床应用评价分析 被引量:1

Evaluation and Analysis of Clinical Application of Tigecycline in a Tertiary Hospital from 2021 to 2023
原文传递
导出
摘要 目的:回顾分析贵州省黔东南苗族侗族自治州人民医院在2021年11月—2023年5月使用过替加环素的患者信息,评价分析使用该药物的合理性、有效性和安全性,以期为临床用药提供参考。方法:使用PASS系统统计使用过替加环素患者的基本信息,包括年龄、性别、科室、临床诊断、细菌药敏试验以及用药方案、联合使用其他抗菌药物情况。通过查阅患者病案资料、治疗过程及药物不良反应记录,分析计算替加环素使用的合理率、有效率和安全率。结果:该医院近2年间共有38例患者使用替加环素,使用合理率为23.68%,治疗有效率为23.68%,药物不良反应发生率为13.16%。结论:该医院替加环素的使用合理率及治疗有效率均偏低,药学部门应加强对临床进行替加环素使用原则、适应证、用法用量及安全性的培训,提高药物使用合理性和有效性,降低药物不良反应发生风险。 Objection:To retrospectively analyze the information of patients who used tigecycline in the People’s Hospital of Qiandongnan Miao and Dong Autonomous Prefecture of Guizhou Province from November 2021 to May 2023,and to evaluate and analyze the rationality,efectiveness and safety of the drug,so as to provide reference for clinical medication.Methods:The PASS system was used to analyze the basic information of patients using tigecycline,including age,gender,department,clinical diagnosis,bacterial drug sensitivity test and drug regimen,combined use of other antibiotics.By consulting the patient’s medical record data,treatment process and adverse drug reaction records,the reasonable rate,efective rate and safety rate of tigecycline use were analyzed and calculated.Results:A total of 38 patients were treated with tigecycline in the hospital in the past two years,the reasonable rate of use was 23.68%,the efective rate of treatment was 23.68%,and the incidence of adverse drug reactions was 13.16%.Conclusion:The rational use rate and efective rate of tigecycline in this hospital are low.The pharmaceutical department should strengthen the training of the principles,indications,usage and dosage and safety of tigecycline in clinical practice,so as to improve the rationality and efectiveness of drug use and reduce the risk of adverse drug reactions.
作者 蔡泽政 唐颖 张梅花 月清仪 张帆 CAI Zezheng;TANG Ying;ZHANG Meihua;YUE Qingyi;ZHANG Fan(Department of Pharmacy,People’s Hospital of Qiandongnan Miao and Dong Autonomous Prefecture,Kaili 556000,Guizhou,China;Department of Pharmacy,People’s Hospital of Hubei Provincial,Wuhan 430000,Hubei,China)
出处 《中国药物滥用防治杂志》 CAS 2024年第4期648-654,共7页 Chinese Journal of Drug Abuse Prevention and Treatment
基金 武汉市科技局曙光计划(编号:2022020801020478)。
关键词 替加环素 临床应用 不良反应 Tigecycline Clinical application Adverse reaction
  • 相关文献

参考文献11

二级参考文献111

  • 1周颖杰,李光辉.成人及儿童复杂性腹腔内感染的诊断与处理:美国外科感染学会及美国感染病学会指南[J].中国感染与化疗杂志,2010,10(4):241-247. 被引量:241
  • 2<应用抗菌药物防治外科感染的指导意见>撰写协作组.应用抗菌药物防治外科感染的指导意见(草案)ⅩⅦ——骨和关节感染[J].中华外科杂志,2005,43(4):270-272. 被引量:43
  • 3Peleg AY, Seifert H, Paterson DLAeinetobaeter baumannii: emergence of a successful pathogen. Clin Micmbiol Rev,2008,21 : 538-582.
  • 4Falagas ME, Koletsi PK, Bliziotis IA.The diversity of definitions of muhidrug-resistant(MDR) and pandrug-resistant (PDR) Aeinetohaeter bsumannli and Pseudomonas aeruginosa.J Med Microbiol, 2006,55: 1619-1629.
  • 5Paterson DL, Doi Y.A step closer to extreme drug resistance(XDR) in gram-negative bacilli.Clin Infect Dis,2007,45: 1179-1181.
  • 6Falagas ME, Karageorgopoulos DE.Pandrug resistance(PDR), extensive drug resistance(XDR), and muhidrug resistance(MDR) among Gram- negative bacilli: need for international harmonization in terminology.Clin Infect Dis, 2008,46: 1121-1122; author reply 1122.
  • 7Zhou H, Yang Q, Yu YS, et al. Clonal Spread of Imipenem-resistant Aeinetobaeter baumannii among different cities of China.J Clin Mierubiol, 2007,45 : 4054-4057.
  • 8Perez F, Hujer AM, Hujer KM, et al.Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother, 2007,51: 3471-3484.
  • 9Munoz-Price LS, Robert AW.Aclinetobaeter Infection.N Engl J Med,2008,358: 1271-1281.
  • 10Guardado AR, Blanco A, Asensi V, et al.Muhidrug-resistant Aeinetohaeter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemother,2008,61 : 908-913.

共引文献1439

同被引文献13

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部